Fifth Third Bancorp Takes Position in Vera Therapeutics, Inc. $VERA

Fifth Third Bancorp purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 35,492 shares of the company’s stock, valued at approximately $1,428,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $46,000. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics in the 2nd quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics in the 4th quarter worth approximately $71,000. Finally, Tower Research Capital LLC TRC boosted its stake in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. Needham & Company LLC set a $125.00 price target on Vera Therapeutics in a research report on Wednesday, July 8th. HC Wainwright raised their price target on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Guggenheim raised their price target on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.58.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $36.35 on Friday. The company has a market cap of $2.61 billion, a PE ratio of -6.56 and a beta of 0.92. The firm’s 50 day moving average price is $37.04 and its 200-day moving average price is $40.17. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 52-week low of $19.07 and a 52-week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the company earned ($0.81) EPS. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -6.37 EPS for the current fiscal year.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 83,250 shares of company stock valued at $3,337,770. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.